Intranasal oxytocin blocks alcohol withdrawal in human subjects
Open accessAbstract
Background: The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol‐dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain. Methods: In a randomized, double‐blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol‐dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for A lcohol (CIWA) score‐driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3. Results: All subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01). Conclusions: This is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative‐hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol‐dependent outpatients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Intranasal oxytocin blocks alcohol withdrawal in humans and reduces the amount of benzodiazepines required for treatment.
“A small study showed that intranasal oxytocin blocked alcohol withdrawal in humans, based on such measures as the Alcohol Withdrawal Symptom Checklist of the Clinical Institute Withdrawal Assessment for Alcohol, and reduced the amount of benzodiazepines that were required for treatment (Pedersen et al., 2013).”
From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Pedersen et al., 2013
Intranasal oxytocin blocks alcohol withdrawal.
“In two recent studies, OXT IN was found to suppress stress-induced craving in cannabis-dependent individuals (134) and to block alcohol withdrawal (135).”
From Dissecting the Role of Oxytocin in the Formation and Loss of Social Relationships (2016) · cites this paper as [135]
Safety and feasibility of daily oxytocin dosing has been demonstrated in other human OT studies including those with alcohol-dependent patients, patients with schizophrenia, and individuals with trauma exposure.
“Safety and feasibility of daily dosing has been demonstrated in other human OT studies including those with alcohol-dependent patients (Pedersen et al., 2013), patients with schizophrenia (Pedersen et al., 2011) and individuals with trauma exposure (van Zuiden et al., 2016).”
From Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: a randomized, placebo-controlled pilot trial (2018) · cites this paper as Pedersen et al., 2013
Intranasal oxytocin produces significantly less craving and anxiety to a social stress task than placebo in marijuana-dependent subjects.
“Others have found that intranasal oxytocin produces significantly less craving and anxiety to a social stress task than placebo in marijuana-dependent subjects (Carson et al., 2013; McRae-Clark et al., 2013; Pedersen et al., 2013).”
From Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence (2015) · cites this paper as Pedersen et al., 2013
Compared with placebo, intranasal oxytocin produces significantly lower symptoms of alcohol withdrawal and anxiety in alcohol-dependent subjects.
“For example, compared with placebo, intranasal oxytocin produced significantly lower symptoms of alcohol withdrawal and anxiety in alcohol-dependent subjects (Pedersen et al., 2013).”
From Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence (2015) · cites this paper as Pedersen et al., 2013
The neuropeptide oxytocin appears to mitigate the effects of stress in individuals with substance use disorders.
“The neuropeptide oxytocin appears to mitigate the effects of stress in individuals with SUDs.”
From Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence (2015) · cites this paper as Pedersen et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139 · see citing works
(1998) · PubMed · Cited by 10,216 · see citing works
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690 · see citing works
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089 · see citing works
Heinrichs, M., Baumgartner, T., Kirschbaum, C., & Ehlert, U. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00465-7 · Cited by 2,091 · see citing works
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · see citing works
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639 · see citing works
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356 · see citing works
Oxytocin improves “mind-reading” in humans
Domes, G., Heinrichs, M., Michel, A., Berger, C., & Herpertz, S. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.015 · Cited by 1,298 · see citing works
Oxytocin shapes the neural circuitry of trust and trust adaptation in humans
Baumgartner, T., Heinrichs, M., Vonlanthen, A., Fischbacher, U., & Fehr, E. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.009 · Cited by 1,258 · see citing works
Oxytocin: The Great Facilitator of Life
Lee, H.-J., Macbeth, A. H., Pagani, J., & Young, W. S. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.04.001 · Cited by 1,037 · see citing works
Promoting social behavior with oxytocin in high-functioning autism spectrum disorders.
Andari, E., Duhamel, J.-R., Zalla, T., Herbrecht, E., Leboyer, M., & Sirigu, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910249107 · Cited by 941 · see citing works
Psychometric properties of the Penn Alcohol Craving Scale
Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04349.x · Cited by 852 · see citing works
Oxytocin increases gaze to the eye region of human faces
Guastella, A. J., Mitchell, P. B., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.026 · Cited by 798 · see citing works
Kushner, M. G. (2000) · Clinical Psychology Review · doi:10.1016/s0272-7358(99)00027-6 · Cited by 782 · see citing works
Sobell, L. C., Sobell, M. B., Leo, G. I., & Cancilla, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 777 · see citing works
Oxytocin attenuates amygdala responses to emotional faces regardless of valence
Domes, G., Heinrichs, M., Gläscher, J., Büchel, C., Braus, D. F., & Herpertz, S. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.025 · Cited by 774 · cited 3× · see citing works
“Animal and human studies have found that OT decreases stress responses including anxiety (Amico et al., 2004; Bale et al., 2001; Domes et al., 2007a; Heinrichs et al., 2003; Kirsch et al., 2005; Mantella et al., 2003; McCarthy et al., 1996; de Oliveira et al., 2011; Ring et al., 2006; Windle et…”
The Peptide That Binds: A Systematic Review of Oxytocin and its Prosocial Effects in Humans
MacDonald, K., & MacDonald, T. M. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673220903523615 · Cited by 585 · see citing works
Effects of intranasal oxytocin on emotional face processing in women
Domes, G., Lischke, A., Berger, C., Grossmann, A., Hauenstein, K., Heinrichs, M., & Herpertz, S. C. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.06.016 · Cited by 521 · cited 1× · see citing works
“…dose) intranasal OT treatment, which appears to result in penetration of a significant amount of the neuropeptide into the brain (Born et al., 2002; Domes et al., 2007a, 2010; Kirsch et al., 2005), increases interpersonal trust and cooperation, improves social cognition, and reduces anxiety…”
Bale, T. L., Davis, A. M., Auger, A. P., Dorsa, D. M., & McCarthy, M. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-07-02546.2001 · Cited by 446 · see citing works
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434 · see citing works
An Anxiolytic Action of Oxytocin is Enhanced by Estrogen in the Mouse
MCCARTHY, M. M., MCDONALD, C. H., BROOKS, P. J., & GOLDMAN, D. (1996) · Physiology & Behavior · doi:10.1016/s0031-9384(96)00212-0 · Cited by 328 · see citing works
Anxiety and stress responses in female oxytocin deficient mice
Amico, J. A., Mantella, R. C., Vollmer, R. R., & Li, X. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01161.x · Cited by 327 · see citing works
Ring, R. H., Malberg, J. E., Potestio, L., Ping, J., Boikess, S., Luo, B., Schechter, L. E., Rizzo, S., Rahman, Z., & Rosenzweig-Lipson, S. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0293-z · Cited by 319 · see citing works
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian, A., Becker, O., Cooper, J., Perry, W., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.039 · Cited by 308 · see citing works
Pedersen, C. A., Gibson, C. M., Rau, S. W., Salimi, K., Smedley, K. L., Casey, R. L., Leserman, J., Jarskog, L. F., & Penn, D. L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.027 · Cited by 305 · see citing works
Self-citationDaeppen, J., Gache, P., Landry, U., Sekera, E., Schweizer, V., Gloor, S., & Yersin, B. (2002) · PubMed · doi:10.1001/archinte.162.10.1117 · Cited by 258 · see citing works
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal
Myrick, H., Malcolm, R., Randall, P. K., Boyle, E., Anton, R. F., Becker, H. C., & Randall, C. L. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.00986.x · Cited by 201 · cited 1× · see citing works
“Treatment of alcohol withdrawal with anticonvulsants such as gabapentin, a nonsedative-hypnotic drug, has been reported to be efficacious for treatment of mild alcohol withdrawal and to decrease postdetoxification anxiety, craving, and drinking (Myrick et al., 2009).”
Female oxytocin-deficient mice display enhanced anxiety-related behavior
Mantella, R. C., Vollmer, R. R., Li, X., & Amico, J. A. (2003) · Endocrinology · doi:10.1210/en.2002-0197 · Cited by 200 · see citing works
Oxytocin and addiction: a review
L. Kovács, G., Sarnyai, Z., & Szabó, G. (1998) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(98)00064-x · Cited by 195 · see citing works
Windle, R. J., Shanks, N., Lightman, S. L., & Ingram, C. D. (1997) · Endocrinology · doi:10.1210/en.138.7.2829 · Cited by 170 · see citing works
Anxiolytic-like effect of oxytocin in the simulated public speaking test
de Oliveira, D. C., Zuardi, A. W., Graeff, F. G., Queiroz, R. H., & Crippa, J. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111400642 · Cited by 154 · see citing works
PHARMACOTHERAPIES FOR ALCOHOL ABUSE
Saitz, R., & O’Malley, S. S. (1997) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70554-x · Cited by 128 · see citing works
Breese, G. R., Knapp, D. J., & Overstreet, D. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300282 · Cited by 115 · see citing works
Intranasal oxytocin in obsessive-compulsive disorder
Epperson, C. N., McDougle, C. J., & Price, L. H. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(96)00120-5 · Cited by 88 · see citing works
Oxytocin in obsessive compulsive disorder
den Boer, J. A., & Westenberg, H. G. M. (1992) · Peptides · doi:10.1016/0196-9781(92)90010-z · Cited by 80 · see citing works
Pittman, B. P., Gueorguieva, R. V., Krupitsky, E. M., Rudenko, A. A., Flannery, B., & Krystal, J. H. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00345.x · Cited by 67 · see citing works
Overstreet, D. H., Knapp, D. J., & Breese, G. R. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00445.x · Cited by 59 · see citing works
The effects of neurohypophyseal hormones on tolerance to the hypothermic effect of ethanol
Szabó, G., Kovács, G. L., Székeli, S., & Telegdy, G. (1985) · Alcohol · doi:10.1016/0741-8329(85)90082-5 · Cited by 44 · see citing works
EFFECTS OF NEUROHYPOPHYSEAL PEPTIDE HORMONES ON ALCOHOL DEPENDENCE AND WITHDRAWAL
Szabó, G., Kovács, G. L., & Telegdy, G. (1987) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a044668 · Cited by 38 · see citing works
Puciklowski, O., Kostowski, W., & Trzaskowska, E. (1985) · Peptides · doi:10.1016/0196-9781(85)90067-1 · Cited by 29 · see citing works
Szabó, G., Kovács, G. L., & Telegdy, G. (1989) · PubMed · Cited by 29 · see citing works
Jodogne, C., Tirelli, E., Klingbiel, P., & Legros, J.-J. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90549-h · Cited by 27 · see citing works
Effects of peptides related to neurohypophyseal hormones on ethanol tolerance
Rigter, H., Dortmans, C., & Crabbe, J. C. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(80)80043-8 · Cited by 21 · see citing works
Baclofen for Alcohol Withdrawal: Not Comparable to the Gold Standard (Benzodiazepines)
Saitz, R. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.015 · Cited by 6 · see citing works
Fitzgerald, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1093 · Cited by 6 · see citing works
Szabó, G., Kovács, G. L., & Telegdy, G. (1988) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
4 of the 51 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The oxytocin receptor: from intracellular signaling to behavior
Jurek, B., & Neumann, I. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00031.2017 · Cited by 999 · see citing works
Uvnäs-Moberg, K., Handlin, L., & Petersson, M. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.01529 · Cited by 351 · see citing works
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337 · see citing works
Substance use during pregnancy
Forray, A. (2016) · F1000Research · doi:10.12688/f1000research.7645.1 · Cited by 316 · see citing works
Immunohistochemical localization of oxytocin receptors in human brain
Boccia, M. L., Petrusz, P., Suzuki, K., Marson, L., & Pedersen, C. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.048 · Cited by 276 · see citing works
Self-citationInfluence of stress associated with chronic alcohol exposure on drinking
Becker, H. C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.028 · Cited by 191 · see citing works
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181 · see citing works
Nose-to-brain peptide delivery – The potential of nanotechnology
Samaridou, E., & Alonso, M. J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.001 · Cited by 178 · see citing works
Pathophysiology of the Effects of Alcohol Abuse on the Endocrine System
Rachdaoui, N. (2017) · Alcohol research · doi:10.35946/arcr.v38.2.08 · Cited by 173 · see citing works
Peris, J., MacFadyen, K. A., Smith, J. A., de Kloet, A. D., Wang, L. A., & Krause, E. G. (2016) · The Journal of Comparative Neurology · doi:10.1002/cne.24116 · Cited by 158 · see citing works
Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat
Bentzley, B. S., Jhou, T. C., & Aston‐Jones, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406324111 · Cited by 151 · see citing works
Buisman‐Pijlman, F. T. A., Sumracki, N. M., Gordon, J. J., Hull, P. R., Carter, C. S., & Mattie Tops, A. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.09.005 · Cited by 143 · see citing works
Oxytocin׳s role in anxiety: A critical appraisal
MacDonald, K., & Feifel, D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.025 · Cited by 139 · see citing works
Dissecting the Role of Oxytocin in the Formation and Loss of Social Relationships
Hurlemann, R., & Scheele, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.05.013 · Cited by 136 · see citing works
Concurrent Treatment of Substance Use and PTSD
Flanagan, J. C., Korte, K. J., Killeen, T. K., & Back, S. E. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0709-y · Cited by 131 · see citing works
Flanagan, J. C., Sippel, L. M., Wahlquist, A., Moran-Santa Maria, M. M., & Back, S. E. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.12.014 · Cited by 117 · see citing works
The Role of the Central Amygdala in Alcohol Dependence
Roberto, M., Kirson, D., & Khom, S. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039339 · Cited by 112 · see citing works
Oxytocin reduces alcohol cue-reactivity in alcohol-dependent rats and humans
Hansson, A. C., Koopmann, A., Uhrig, S., Bühler, S., Domi, E., Kiessling, E., Ciccocioppo, R., Froemke, R. C., Grinevich, V., Kiefer, F., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.257 · Cited by 109 · see citing works
Oxytocin for the treatment of drug and alcohol use disorders
Lee, M. R., & Weerts, E. M. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000258 · Cited by 105 · see citing works
Tunstall, B. J., Kirson, D., Zallar, L. J., McConnell, S. A., Vendruscolo, J. C. M., Ho, C. P., Oleata, C. S., Khom, S., Manning, M., Lee, M. R., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.2006421 · Cited by 104 · see citing works
Oxytocin inhibits ethanol consumption and ethanol‐induced dopamine release in the nucleus accumbens
Peters, S., Bowen, M. T., Bohrer, K., McGregor, I. S., & Neumann, I. D. (2016) · Addiction Biology · doi:10.1111/adb.12362 · Cited by 99 · see citing works
Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
Lee, M. R., Rohn, M. C. H., Tanda, G., & Leggio, L. (2016) · CNS Drugs · doi:10.1007/s40263-016-0313-z · Cited by 97 · see citing works
Oxytocin Acts in Nucleus Accumbens to Attenuate Methamphetamine Seeking and Demand
Cox, B. M., Bentzley, B. S., Regen-Tuero, H. C., See, R. E., Reichel, C. M., & Aston‐Jones, G. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.11.011 · Cited by 98 · see citing works
Medications for alcohol use disorders: An overview
Akbar, M. D., Egli, M., Cho, Y., Song, B., & Noronha, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 97 · see citing works
Evidence for Intranasal Oxytocin Delivery to the brain: Recent Advances and Future Perspectives
Quintana, D. S., Smerud, K. T., Andreassen, O. A., & Djupesland, P. G. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0002 · Cited by 94 · see citing works
Oxytocin reduces ethanol self-administration in mice
King, C. E., Griffin, W. C., Luderman, L. N., Kates, M. M., McGinty, J. F., & Becker, H. C. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13359 · Cited by 89 · see citing works
Mitchell, J. M., Arcuni, P. A., Weinstein, D., & Woolley, J. D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000213 · Cited by 82 · see citing works
Early adverse experience and substance addiction: Dopamine, oxytocin, and glucocorticoid pathways
Kim, S., Kwok, S., Mayes, L. C., Potenza, M. N., Rutherford, H. J. V., & Strathearn, L. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13140 · Cited by 85 · see citing works
Rebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction
Bowen, M. T., & Neumann, I. D. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.10.003 · Cited by 83 · see citing works
Peripheral oxytocin administration reduces ethanol consumption in rats
MacFadyen, K., Loveless, R., DeLucca, B., Wardley, K., Deogan, S., Thomas, C., & Peris, J. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.014 · Cited by 76 · see citing works
Bowen, M. T., Peters, S. T., Absalom, N. L., Chebib, M., Neumann, I. D., & McGregor, I. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416900112 · Cited by 72 · see citing works
Oxytocin and Rodent Models of Addiction
Leong, K.-C., Cox, S. S., King, C. E., Becker, H. C., & Reichel, C. M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.007 · Cited by 69 · see citing works
The role of oxytocin in alcohol and drug abuse
King, C. E., Gano, A., & Becker, H. C. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146761 · Cited by 66 · see citing works
Horta, M., Kaylor, K., Feifel, D., & Ebner, N. C. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.012 · Cited by 62 · see citing works
Oxytocin enhances cognitive control of food craving in women
Striepens, N., Schröter, F., Stoffel‐Wagner, B., Maier, W., Hurlemann, R., & Scheele, D. (2016) · Human Brain Mapping · doi:10.1002/hbm.23308 · Cited by 63 · see citing works
Yardley, M. M., & Ray, L. A. (2016) · Addiction Biology · doi:10.1111/adb.12349 · Cited by 60 · see citing works
Zhou, L., Sun, W., Young, A. B., Lee, K., McGinty, J. F., & See, R. E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu009 · Cited by 57 · see citing works
Flanagan, J. C., Baker, N. L., McRae-Clark, A. L., Brady, K. T., & Moran-Santa Maria, M. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.064 · Cited by 56 · see citing works
Oxytocin and opioid addiction revisited: old drug, new applications
Zanos, P., Georgiou, P., Weber, C. D., Robinson, F., Kouimtsidis, C., Niforooshan, R., & Bailey, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13757 · Cited by 54 · see citing works
Drug addiction: An affective-cognitive disorder in need of a cure
Fattore, L., & Diana, M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.006 · Cited by 55 · see citing works
Oxytocin, Tolerance, and the Dark Side of Addiction
Pedersen, C. A. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.08.003 · Cited by 58 · see citing works
Self-citationOxytocin attenuates stress-induced reinstatement of alcohol seeking behavior in male and female mice
King, C. E., & Becker, H. C. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05233-z · Cited by 53 · see citing works
Everett, N. A., Turner, A. J., Costa, P. A., Baracz, S. J., & Cornish, J. L. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0719-7 · Cited by 52 · see citing works
Complexity of oxytocin׳s effects in a chronic cocaine dependent population
Lee, M. R., Glassman, M., King‐Casas, B., Kelly, D. L., Stein, E. A., Schroeder, J. R., & Salmeron, B. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.005 · Cited by 51 · see citing works
Baracz, S. J., Everett, N. A., & Cornish, J. L. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.08.014 · Cited by 52 · see citing works
Gil, M., Bhatt, R., Picotte, K. B., & Hull, E. M. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.02.002 · Cited by 50 · see citing works
Regionally Specific Effects of Oxytocin on Reinstatement of Cocaine Seeking in Male and Female Rats
Weber, R. A., Logan, C. N., Leong, K.-C., Peris, J., Knackstedt, L. A., & Reichel, C. M. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy025 · Cited by 48 · see citing works
Stauffer, C. S., Musinipally, V., Suen, A. O., Lynch, K. L., Shapiro, B. J., & Woolley, J. D. (2016) · Addiction Research & Theory · doi:10.3109/16066359.2016.1173682 · Cited by 47 · see citing works
Emerging pharmacotherapies for alcohol use disorder
Mason, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.032 · Cited by 46 · see citing works
Oxytocin reduces alcohol consumption in prairie voles
Stevenson, J. R., Wenner, S. M., Freestone, D. M., Romaine, C. C., Parian, M. C., Christian, S. M., Bohidar, A. E., Ndem‐Galbert, J. R., Vogel, I., & O'Kane, C. M. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.07.021 · Cited by 47 · see citing works
Bernheim, A. P., Leong, K.-C., Berini, C., & Reichel, C. M. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.08.012 · Cited by 47 · see citing works
Schindler, E., Wallace, R., Sloshower, J., & D'Souza, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 42 · see citing works
The neurocircuitry involved in oxytocin modulation of methamphetamine addiction
Baracz, S. J., & Cornish, J. L. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.08.001 · Cited by 46 · see citing works
Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier
Aly, A. E.-E., & Waszczak, B. L. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1069815 · Cited by 45 · see citing works
Woolley, J. D., Arcuni, P. A., Stauffer, C. S., Fulford, D., Carson, D. S., Batki, S., & Vinogradov, S. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4308-8 · Cited by 45 · see citing works
Hofmann, S. G., Fang, A., & Brager, D. N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.039 · Cited by 44 · see citing works
RetractedFlanagan, J. C., Hand, A., Jarnecke, A. M., Maria, M. M. M., Brady, K. T., & Joseph, J. E. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000197 · Cited by 45 · see citing works
Morley, K. C., Perry, C. J., Watt, J., Hurzeler, T. P., Leggio, L., Lawrence, A. J., & Haber, P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892641 · Cited by 44 · see citing works
Johnston, J., Lintzeris, N., Allsop, D. J., Suraev, A. S., Booth, J., Carson, D. S., Helliwell, D., WINSTOCK, A. R., & McGregor, I. S. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3611-5 · Cited by 43 · see citing works
Opioid addiction: who are your real friends?
Eitan, S., Emery, M. A., Bates, M. L. S., & Horrax, C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.017 · Cited by 42 · see citing works
Flanagan, J. C., Allan, N. P., Calhoun, C. D., Badour, C. L., Maria, M. M. M., Brady, K. T., & Back, S. E. (2018) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000232 · Cited by 43 · see citing works
Oxytocin prevents the increase of cocaine-related responses produced by social defeat
Perez, C. F., Castro‐Zavala, A., Luján, M. Á., Filarowska, J., Ballestín, R., Miñarro, J., Valverde, O., & Rodríguez‐Arias, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.011 · Cited by 40 · see citing works
The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
Berardis, D. D., Marini, S., Iasevoli, F., Tomasetti, C., de Bartolomeis, A., Mazza, M., Valchera, A., Fornaro, M., Cavuto, M., Srinivasan, V., et al. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312020012 · Cited by 38 · see citing works
Bahí, A., Mansouri, S. A., & Maamari, E. A. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.06.009 · Cited by 38 · see citing works
Vaht, M., Kurrikoff, T., Laas, K., Veidebaum, T., & Harro, J. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.09.018 · Cited by 37 · see citing works
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34 · see citing works
Vasopressin and alcohol: a multifaceted relationship
Harper, K. M., Knapp, D. J., Criswell, H. E., & Breese, G. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5099-x · Cited by 34 · see citing works
Melby, K., Gråwe, R. W., Aamo, T. O., Salvesen, Ø., & Spigset, O. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.003 · Cited by 33 · see citing works
Lee, M. R., Schwandt, M. L., Sankar, V., Suchankova, P., Sun, H., & Leggio, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.07.481 · Cited by 33 · see citing works
Vena, A. A., Zandy, S. L., Cofresí, R. U., & Gonzales, R. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107573 · Cited by 32 · see citing works
Bardo, M. T., Hammerslag, L. R., & Malone, S. G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108567 · Cited by 32 · see citing works
Impact of intranasal oxytocin on interoceptive accuracy in alcohol users: an attentional mechanism?
Betka, S., van Praag, C. G., Paloyelis, Y., Bond, R., Pfeifer, G., Sequeira, H., Duka, T., & Critchley, H. (2018) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsy027 · Cited by 30 · see citing works
Snider, B. M., Geiser, A., Yu, X.-P., Beebe, E., Willency, J. A., Qing, K., Guo, L., Lu, J., Wang, X., Yang, Q., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00004 · Cited by 32 · see citing works
Bach, P., Reinhard, I., Bühler, S., Vollstädt‐Klein, S., Kiefer, F., & Koopmann, A. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104385 · Cited by 29 · see citing works
Oxytocin and Addiction: Potential Glutamatergic Mechanisms
Sundar, M., Patel, D., Young, Z., & Leong, K.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052405 · Cited by 29 · see citing works
Oxytozin: Evidenz für ein therapeutisches Potenzial des sozialen Neuromodulators
Eckstein, M., & Hurlemann, R. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3832-6 · Cited by 28 · see citing works
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 29 · see citing works
Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges
Che, X., Cai, J., Liu, Y., Xu, T., Yang, J., & Wu, C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107820 · Cited by 28 · see citing works
Romantic Love vs. Drug Addiction May Inspire a New Treatment for Addiction
Zou, Z., Song, H., Zhang, Y., & Zhang, X. (2016) · Frontiers in Psychology · doi:10.3389/fpsyg.2016.01436 · Cited by 28 · see citing works
Bowen, M. T., & Neumann, I. D. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_17 · Cited by 28 · see citing works
Flanagan, J. C., Fischer, M. S., Nietert, P. J., Back, S. E., Maria, M. M.-S., Snead, A., & Brady, K. T. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2017.12.003 · Cited by 27 · see citing works
Factors contributing to the escalation of alcohol consumption
Bowen, M. T., George, O., Muskiewicz, D. E., & Hall, F. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.017 · Cited by 27 · see citing works
Dunigan, A. I., & Roseberry, A. G. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100011 · Cited by 28 · see citing works
Mellentin, A. I., Finn, S. W., Skøt, L., Thaysen‐Petersen, D., Mistarz, N. T., Fink‐Jensen, A., & Nielsen, D. G. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105185 · Cited by 24 · see citing works
Giannotti, G., Mottarlini, F., Heinsbroek, J. A., Mandel, M. R., James, M. H., & Peters, J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02161-z · Cited by 25 · see citing works
Oxytocin modulates hemodynamic responses to monetary incentives in humans
Mickey, B. J., Heffernan, J., Heisel, C. J., Peciña, M., Hsu, D. T., Zubieta, J.-K., & Love, T. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4423-6 · Cited by 24 · see citing works
Stevenson, J. R., Young, K., Bohidar, A. E., Francomacaro, L. M., Fasold, T. R., Buirkle, J. M., Ndem‐Galbert, J. R., & Christian, S. C. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13430 · Cited by 25 · see citing works
Alcohol and oxytocin: Scrutinizing the relationship
Ryabinin, A. E., & Fulenwider, H. D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.009 · Cited by 23 · see citing works
Can intranasal oxytocin reduce craving in automated addictive behaviours? A systematic review
Houghton, B., Kouimtsidis, C., Duka, T., Paloyelis, Y., & Bailey, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15617 · Cited by 23 · see citing works
Oxytocin treatment in pediatric populations
Taylor, A. E., Lee, H.-E., & Buisman‐Pijlman, F. T. A. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00360 · Cited by 23 · see citing works
Hicks, C., Ramos, L., Dampney, B., Baracz, S. J., McGregor, I. S., & Hunt, G. E. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.10.005 · Cited by 22 · see citing works
L’ocytocine et la dépression du post-partum
Cardaillac, C., Rua, C., Simon, E. G., & El‐Hage, W. (2016) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2016.05.002 · Cited by 22 · see citing works
Melby, K., Gråwe, R. W., Aamo, T. O., Skovlund, E., & Spigset, O. (2020) · Alcohol and Alcoholism · doi:10.1093/alcalc/agaa133 · Cited by 22 · see citing works
Systemic oxytocin administration alters mesolimbic dopamine release in mice
Estes, M. K., Freels, T. G., Prater, W. T., & Lester, D. B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.006 · Cited by 22 · see citing works
Verplaetse, T. L. (2018) · Alcohol research · doi:10.35946/arcr.v39.2.09 · Cited by 22 · see citing works
Decreased Blood Levels of Oxytocin in Ketamine-Dependent Patients During Early Abstinence
Huang, M., Chen, L., Chang, H., Liang, X., Chen, C., Cheng, W., & Xu, K. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00633 · Cited by 21 · see citing works
Oxytocin treatment for alcoholism: Potential neurocircuitry targets
Peris, J., Steck, M. R., & Krause, E. G. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108091 · Cited by 21 · see citing works
King, C. E., Griffin, W. C., Lopez, M. F., & Becker, H. C. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01046-x · Cited by 21 · see citing works
Brust, J. C. M. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62619-6.00008-2 · Cited by 21 · see citing works
Walcott, A. T., & Ryabinin, A. E. (2020) · Addiction Biology · doi:10.1111/adb.12893 · Cited by 21 · see citing works
- Authors
- Pedersen, C. A., Smedley, K. L., Leserman, J., Jarskog, L. F., Rau, S. W., Kampov‐Polevoi, A., Casey, R. L., Fender, T., & Garbutt, J. C.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Pedersen, Cort A.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2012-10
- Volume
- 37
- Issue
- 3
- Pages
- 484-489
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- PMC
- PMC3557665
- OpenAlex
- W2073015613
- Cited by
- 196
- References
- 51
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 8 · 2023: 8 · 2022: 16 · 2021: 16 · 2020: 16 · 2019: 12 · 2018: 23 · 2017: 28 · 2016: 23 · 2015: 9 · 2014: 12 · 2013: 9 · 2012: 2
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alcoholism Clinical and Experimental Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (5-P60-AA011605-08-13, P60AA011605)
- National Center for Research Resources (UL1RR025747)
- Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Neurology › Alcoholism and Thiamine Deficiency
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- oxytocin, intranasal administration, alcohol withdrawal, alcoholism, alcohol detoxification, alcohol craving, anxiety, mood states, benzodiazepine tolerance, neural adaptation
- MeSH terms
- Administration, Intranasal, Adult, Alcoholism, Double-Blind Method, Female, Humans, Male, Middle Aged, Oxytocin, Pilot Projects, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
